9IB Stock Overview
A clinical stage pharmaceutical company, develops drugs to prevent serious neonatal diseases affecting premature infants in Sweden. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Infant Bacterial Therapeutics AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 4.21 |
| 52 Week High | SEK 9.10 |
| 52 Week Low | SEK 2.75 |
| Beta | 1.06 |
| 1 Month Change | 28.75% |
| 3 Month Change | 34.94% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | -67.41% |
| Change since IPO | -58.95% |
Recent News & Updates
Recent updates
Shareholder Returns
| 9IB | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -6.7% | -0.3% | -0.3% |
| 1Y | n/a | -17.0% | 7.0% |
Return vs Industry: Insufficient data to determine how 9IB performed against the German Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how 9IB performed against the German Market.
Price Volatility
| 9IB volatility | |
|---|---|
| 9IB Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 5.5% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.6% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 9IB's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine 9IB's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 10 | Staffan Stromberg | www.ibtherapeutics.com |
Infant Bacterial Therapeutics AB (publ), a clinical stage pharmaceutical company, develops drugs to prevent serious neonatal diseases affecting premature infants in Sweden. The company's lead drug candidate is IBP-9414, which is in Phase III clinical studies `to prevent necrotizing enterocolitis, as well as to improve feeding tolerance in premature infants. It is also developing IBP-1016 for the treatment of gastroschisis, a rare and severe birth abnormality in infants.
Infant Bacterial Therapeutics AB (publ) Fundamentals Summary
| 9IB fundamental statistics | |
|---|---|
| Market cap | €65.44m |
| Earnings (TTM) | -€12.49m |
| Revenue (TTM) | €433.74 |
Over9,999x
P/S Ratio-5.2x
P/E RatioIs 9IB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 9IB income statement (TTM) | |
|---|---|
| Revenue | SEK 5.00k |
| Cost of Revenue | SEK 0 |
| Gross Profit | SEK 5.00k |
| Other Expenses | SEK 144.04m |
| Earnings | -SEK 144.03m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 13, 2025
| Earnings per share (EPS) | -10.69 |
| Gross Margin | 100.00% |
| Net Profit Margin | -2,880,640.00% |
| Debt/Equity Ratio | 0% |
How did 9IB perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/25 06:35 |
| End of Day Share Price | 2024/12/19 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Infant Bacterial Therapeutics AB (publ) is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|